Psychedelic Drugs Market
Psychedelic Drugs Market Analysis By Source (Natural Psychedelic Drugs, Synthetic Psychedelic Drugs), By Therapeutic Drug(Psilocybin, LSD, MDMA, DMT, Ketamine), By Indication, By Route of Administration - Global Forecast 2021-2031
Analysis of Psychedelic Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Market Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Global GDP Outlook 4.1.2. Global Per Capita Income 4.1.3. Global Healthcare Spending 4.2. Forecast Factors - Relevance & Impact 4.2.1. Rise in Awareness and prevalence of Mental Health Disorders 4.2.2. Increasing Research Opportunities in Psychedelic Drug Therapeutics 4.2.3. Rising Ageing Population 4.2.4. Impact of COVID on Future Trends 4.2.5. Regulatory Impact 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 5. COVID19 Crisis Analysis 5.1. Current COVID19 Statistics and Probable Future Impact 5.2. Current GDP Projection and Probable Impact 5.3. Current Economic Projection as compared to 2008 financial analysis 5.4. COVID19 and Impact Analysis 5.4.1. By Source 5.4.2. By Therapeutic Drug 5.4.3. By Indication 5.4.4. By Distribution Channel 5.4.5. By Route of Administration 5.4.6. By Region 5.5. 2020 Market Scenario 5.6. Projected recovery Quarter 5.7. Recovery Scenario – Short term, Midterm and Long Term Impact 6. Market Context 6.1. Key Adoption Analysis 6.2. Key Manufacturers Promotional Strategies 6.3. Technology Advancements 6.4. Pipeline Analysis 7. Global Psychedelic Drugs Market Value Analysis 2016 – 2020 and Forecast, 2021 - 2031 7.1. Historical Market Value (US$ Mn) Analysis, 2016 – 2020 7.2. Current and Future Market Value (US$ Mn) Projections, 2021 - 2031 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , By Source 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Source, 2016 – 2020 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2021 - 2031 8.3.1. Natural 8.3.2. Synthetic 8.4. Market Attractiveness Analysis By Source 9. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , By Therapeutic Drug 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Drug, 2016 – 2020 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Drug, 2021 - 2031 9.3.1. Psilocybin 9.3.2. LSD 9.3.3. MDMA (3,4-methylenedioxy-N-methylamphetamine) 9.3.4. N,N-dimethyltryptamine (DMT) 9.3.5. Ketamine 9.4. Market Attractiveness Analysis By Therapeutic Drug 10. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2016 – 2020 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2031 10.3.1. Depressive Disorders 10.3.2. PTSD 10.3.3. Substance Abuse Disorders 10.3.4. OCD 10.3.5. Alzheimer Dementia 10.3.6. Cluster Headaches 10.3.7. Terminal Cancer Distress 10.3.8. Anorexia and Obesity 10.3.9. Personality Disorders 10.3.10. Anxiety 10.4. Market Attractiveness Analysis By Indication 11. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , By Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2016 – 2020 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2021 - 2031 11.3.1. Oral 11.3.1.1. Liquid 11.3.1.2. Capsule 11.3.1.3. Tablet 11.3.2. Injectable 11.3.2.1. Intramuscular 11.3.2.2. Subcutaneous 11.3.2.3. Intrathecal 11.3.3. Rectal 11.3.4. Nasal 11.3.5. Transdermal 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , By Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016 – 2020 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021 - 2031 12.3.1. Online Pharmacies 12.3.2. Hospital Pharmacies 12.3.2.1. Institutional Sales 12.3.2.2. Retail Sales 12.3.3. Retail Pharmacies 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 , by Region 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 – 2020 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2031 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. South Asia 13.3.5. East Asia 13.3.6. Oceania 13.3.7. Middle East and Africa 13.4. Market Attractiveness Analysis By Region 14. North America Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031 14.3.1. By Country 14.3.1.1. U.S. 14.3.1.2. Canada 14.3.2. By Source 14.3.3. By Therapeutic Drug 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Latin America Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031 15.3.1. By Country 15.3.1.1. Brazil 15.3.1.2. Mexico 15.3.1.3. Rest of Latin America 15.3.2. By Source 15.3.3. By Therapeutic Drug 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Europe Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 16.3. Market Size (US$ Mn) By Market Taxonomy, 2021 - 2031 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. Italy 16.3.1.3. France 16.3.1.4. U.K. 16.3.1.5. Spain 16.3.1.6. Russia 16.3.1.7. Rest of Europe 16.3.2. By Source 16.3.3. By Therapeutic Drug 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. South Asia Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 17.3. Market Size (US$ Mn) By Market Taxonomy, 2021 - 2031 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Thailand 17.3.1.3. Indonesia 17.3.1.4. Malaysia 17.3.1.5. Rest of South Asia 17.3.2. By Source 17.3.3. By Therapeutic Drug 17.3.4. By Indication 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. East Asia Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 18.3. Market Size (US$ Mn) By Market Taxonomy, 2021 - 2031 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Source 18.3.3. By Therapeutic Drug 18.3.4. By Indication 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Oceania Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 19.3. Market Size (US$ Mn) By Market Taxonomy, 2021 - 2031 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Source 19.3.3. By Therapeutic Drug 19.3.4. By Indication 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 20. MEA Psychedelic Drugs Market Analysis 2016 – 2020 and Forecast 2021 - 2031 20.1. Introduction 20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 – 2020 20.3. Market Size (US$ Mn) By Market Taxonomy, 2021 - 2031 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Turkey 20.3.1.3. South Africa 20.3.1.4. Rest of MEA 20.3.2. By Source 20.3.3. By Therapeutic Drug 20.3.4. By Indication 20.3.5. By Distribution Channel 20.4. Market Attractiveness Analysis 20.5. Key Market Participants - Intensity Mapping 20.6. Drivers and Restraints - Impact Analysis 21. Key and Emerging Countries Psychedelic Drugs Market Size (US$ Mn) Analysis 2021 & 2031 21.1. Introduction 21.1.1. Market Value Proportion Analysis, By Key Countries 21.1.2. Global Vs. Country Growth Comparison 21.2. U.S. Psychedelic Drugs Market Analysis 21.2.1. By Source 21.2.2. By Therapeutic Drug 21.2.3. By Indication 21.2.4. By Distribution Channel 21.3. Canada Psychedelic Drugs Market Analysis 21.3.1. By Source 21.3.2. By Therapeutic Drug 21.3.3. By Indication 21.3.4. By Distribution Channel 21.4. Brazil Psychedelic Drugs Market Analysis 21.4.1. By Source 21.4.2. By Therapeutic Drug 21.4.3. By Indication 21.4.4. By Distribution Channel 21.5. Mexico Psychedelic Drugs Market Analysis 21.5.1. By Source 21.5.2. By Therapeutic Drug 21.5.3. By Indication 21.5.4. By Distribution Channel 21.6. U.K. Psychedelic Drugs Market Analysis 21.6.1. By Source 21.6.2. By Therapeutic Drug 21.6.3. By Indication 21.6.4. By Distribution Channel 21.7. Germany Psychedelic Drugs Market Analysis 21.7.1. By Source 21.7.2. By Therapeutic Drug 21.7.3. By Indication 21.7.4. By Distribution Channel 21.8. France Psychedelic Drugs Market Analysis 21.8.1. By Source 21.8.2. By Therapeutic Drug 21.8.3. By Indication 21.8.4. By Distribution Channel 21.9. Italy Psychedelic Drugs Market Analysis 21.9.1. By Source 21.9.2. By Therapeutic Drug 21.9.3. By Indication 21.9.4. By Distribution Channel 21.10. Spain Psychedelic Drugs Market Analysis 21.10.1. By Source 21.10.2. By Therapeutic Drug 21.10.3. By Indication 21.10.4. By Distribution Channel 21.11. BENELUX Psychedelic Drugs Market Analysis 21.11.1. By Source 21.11.2. By Therapeutic Drug 21.11.3. By Indication 21.11.4. By Distribution Channel 21.12. Russia Psychedelic Drugs Market Analysis 21.12.1. By Source 21.12.2. By Therapeutic Drug 21.12.3. By Indication 21.12.4. By Distribution Channel 21.13. China Psychedelic Drugs Market Analysis 21.13.1. By Source 21.13.2. By Therapeutic Drug 21.13.3. By Indication 21.13.4. By Distribution Channel 21.14. Japan Psychedelic Drugs Market Analysis 21.14.1. By Source 21.14.2. By Therapeutic Drug 21.14.3. By Indication 21.14.4. By Distribution Channel 21.15. South Korea Psychedelic Drugs Market Analysis 21.15.1. By Source 21.15.2. By Therapeutic Drug 21.15.3. By Indication 21.15.4. By Distribution Channel 21.16. India Psychedelic Drugs Market Analysis 21.16.1. By Source 21.16.2. By Therapeutic Drug 21.16.3. By Indication 21.16.4. By Distribution Channel 21.17. Thailand Psychedelic Drugs Market Analysis 21.17.1. By Source 21.17.2. By Therapeutic Drug 21.17.3. By Indication 21.17.4. By Distribution Channel 21.18. Indonesia Psychedelic Drugs Market Analysis 21.18.1. By Source 21.18.2. By Therapeutic Drug 21.18.3. By Indication 21.18.4. By Distribution Channel 21.19. Malaysia Psychedelic Drugs Market Analysis 21.19.1. By Source 21.19.2. By Therapeutic Drug 21.19.3. By Indication 21.19.4. By Distribution Channel 21.20. Australia Psychedelic Drugs Market Analysis 21.20.1. By Source 21.20.2. By Therapeutic Drug 21.20.3. By Indication 21.20.4. By Distribution Channel 21.21. New Zealand Psychedelic Drugs Market Analysis 21.21.1. By Source 21.21.2. By Therapeutic Drug 21.21.3. By Indication 21.21.4. By Distribution Channel 21.22. GCC Countries Psychedelic Drugs Market Analysis 21.22.1. By Source 21.22.2. By Therapeutic Drug 21.22.3. By Indication 21.22.4. By Distribution Channel 21.23. Turkey Psychedelic Drugs Market Analysis 21.23.1. By Source 21.23.2. By Therapeutic Drug 21.23.3. By Indication 21.23.4. By Distribution Channel 21.24. South Africa Psychedelic Drugs Market Analysis 21.24.1. By Source 21.24.2. By Therapeutic Drug 21.24.3. By Indication 21.24.4. By Distribution Channel 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Concentration 22.3. Market Share Analysis of Top Players 22.4. Market Presence Analysis 22.4.1. By Regional footprint of Players 22.4.2. Technology foot print by Players 22.4.3. Channel Foot Print by Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Janssen Global Services, LLC 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Analyst Commentary 23.3.1.4. Key Financials 23.3.1.5. Recent Developments 23.3.1.6. Sales Footprint 23.3.1.7. Strategy Overview 23.3.1.7.1. Marketing Strategy 23.3.1.7.2. Technology Strategy 23.3.1.7.3. Channel Strategy 23.3.2. ATAI LIFE SCIENCES N.V. 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Analyst Commentary 23.3.2.4. Key Financials 23.3.2.5. Recent Developments 23.3.2.6. Sales Footprint 23.3.2.7. Strategy Overview 23.3.2.7.1. Marketing Strategy 23.3.2.7.2. Technology Strategy 23.3.2.7.3. Channel Strategy 23.3.3. Acadia Pharmaceuticals Inc. 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Analyst Commentary 23.3.3.4. Key Financials 23.3.3.5. Recent Developments 23.3.3.6. Sales Footprint 23.3.3.7. Strategy Overview 23.3.3.7.1. Marketing Strategy 23.3.3.7.2. Technology Strategy 23.3.3.7.3. Channel Strategy 23.3.4. COMPASS 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Analyst Commentary 23.3.4.4. Key Financials 23.3.4.5. Recent Developments 23.3.4.6. Sales Footprint 23.3.4.7. Strategy Overview 23.3.4.7.1. Marketing Strategy 23.3.4.7.2. Technology Strategy 23.3.4.7.3. Channel Strategy 23.3.5. Mind Medicine Inc. 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Analyst Commentary 23.3.5.4. Key Financials 23.3.5.5. Recent Developments 23.3.5.6. Sales Footprint 23.3.5.7. Strategy Overview 23.3.5.7.1. Marketing Strategy 23.3.5.7.2. Technology Strategy 23.3.5.7.3. Channel Strategy 23.3.6. DemeRx, Inc. 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Analyst Commentary 23.3.6.4. Key Financials 23.3.6.5. Recent Developments 23.3.6.6. Sales Footprint 23.3.6.7. Strategy Overview 23.3.6.7.1. Marketing Strategy 23.3.6.7.2. Technology Strategy 23.3.6.7.3. Channel Strategy 23.3.7. Eleusis Holdings Ltd 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Analyst Commentary 23.3.7.4. Key Financials 23.3.7.5. Recent Developments 23.3.7.6. Sales Footprint 23.3.7.7. Strategy Overview 23.3.7.7.1. Marketing Strategy 23.3.7.7.2. Technology Strategy 23.3.7.7.3. Channel Strategy 23.3.8. Small Pharma Inc. 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Analyst Commentary 23.3.8.4. Key Financials 23.3.8.5. Recent Developments 23.3.8.6. Sales Footprint 23.3.8.7. Strategy Overview 23.3.8.7.1. Marketing Strategy 23.3.8.7.2. Technology Strategy 23.3.8.7.3. Channel Strategy 23.3.9. Awakn Life Sciences Corp 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Analyst Commentary 23.3.9.4. Key Financials 23.3.9.5. Recent Developments 23.3.9.6. Sales Footprint 23.3.9.7. Strategy Overview 23.3.9.7.1. Marketing Strategy 23.3.9.7.2. Technology Strategy 23.3.9.7.3. Channel Strategy 23.3.10. OCTARINE BIO 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Analyst Commentary 23.3.10.4. Key Financials 23.3.10.5. Recent Developments 23.3.10.6. Sales Footprint 23.3.10.7. Strategy Overview 23.3.10.7.1. Marketing Strategy 23.3.10.7.2. Technology Strategy 23.3.10.7.3. Channel Strategy 23.3.11. Revive Therapeutics Ltd. 23.3.11.1. Overview 23.3.11.2. Product Portfolio 23.3.11.3. Analyst Commentary 23.3.11.4. Key Financials 23.3.11.5. Recent Developments 23.3.11.6. Sales Footprint 23.3.11.7. Strategy Overview 23.3.11.7.1. Marketing Strategy 23.3.11.7.2. Technology Strategy 23.3.11.7.3. Channel Strategy 23.3.12. Cybin Corp. 23.3.12.1. Overview 23.3.12.2. Product Portfolio 23.3.12.3. Analyst Commentary 23.3.12.4. Key Financials 23.3.12.5. Recent Developments 23.3.12.6. Sales Footprint 23.3.12.7. Strategy Overview 23.3.12.7.1. Marketing Strategy 23.3.12.7.2. Technology Strategy 23.3.12.7.3. Channel Strategy 23.3.13. PharmaTher Holdings Ltd. 23.3.13.1. Overview 23.3.13.2. Product Portfolio 23.3.13.3. Analyst Commentary 23.3.13.4. Key Financials 23.3.13.5. Recent Developments 23.3.13.6. Sales Footprint 23.3.13.7. Strategy Overview 23.3.13.7.1. Marketing Strategy 23.3.13.7.2. Technology Strategy 23.3.13.7.3. Channel Strategy 23.3.14. Mydecine Innovations Group Inc. 23.3.14.1. Overview 23.3.14.2. Product Portfolio 23.3.14.3. Analyst Commentary 23.3.14.4. Key Financials 23.3.14.5. Recent Developments 23.3.14.6. Sales Footprint 23.3.14.7. Strategy Overview 23.3.14.7.1. Marketing Strategy 23.3.14.7.2. Technology Strategy 23.3.14.7.3. Channel Strategy 23.3.15. HAVN Research Inc. 23.3.15.1. Overview 23.3.15.2. Product Portfolio 23.3.15.3. Analyst Commentary 23.3.15.4. Key Financials 23.3.15.5. Recent Developments 23.3.15.6. Sales Footprint 23.3.15.7. Strategy Overview 23.3.15.7.1. Marketing Strategy 23.3.15.7.2. Technology Strategy 23.3.15.7.3. Channel Strategy 23.3.16. Tactogen 23.3.16.1. Overview 23.3.16.2. Product Portfolio 23.3.16.3. Analyst Commentary 23.3.16.4. Key Financials 23.3.16.5. Recent Developments 23.3.16.6. Sales Footprint 23.3.16.7. Strategy Overview 23.3.16.7.1. Marketing Strategy 23.3.16.7.2. Technology Strategy 23.3.16.7.3. Channel Strategy 23.3.17. Gilgamesh 23.3.17.1. Overview 23.3.17.2. Product Portfolio 23.3.17.3. Analyst Commentary 23.3.17.4. Key Financials 23.3.17.5. Recent Developments 23.3.17.6. Sales Footprint 23.3.17.7. Strategy Overview 23.3.17.7.1. Marketing Strategy 23.3.17.7.2. Technology Strategy 23.3.17.7.3. Channel Strategy 23.3.18. GABA Therapeutics, Inc 23.3.18.1. Overview 23.3.18.2. Product Portfolio 23.3.18.3. Analyst Commentary 23.3.18.4. Key Financials 23.3.18.5. Recent Developments 23.3.18.6. Sales Footprint 23.3.18.7. Strategy Overview 23.3.18.7.1. Marketing Strategy 23.3.18.7.2. Technology Strategy 23.3.18.7.3. Channel Strategy 23.3.19. Seelos Therapeutics 23.3.19.1. Overview 23.3.19.2. Product Portfolio 23.3.19.3. Analyst Commentary 23.3.19.4. Key Financials 23.3.19.5. Recent Developments 23.3.19.6. Sales Footprint 23.3.19.7. Strategy Overview 23.3.19.7.1. Marketing Strategy 23.3.19.7.2. Technology Strategy 23.3.19.7.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 2: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 3: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 4: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 5: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 6: Global Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region
Table 7: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 8: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 9: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 10: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 11: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 12: North America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 13: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 14: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 15: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 16: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 17: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 18: Latin America Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 19: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 20: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 21: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 22: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 23: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 24: Europe Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 25: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 26: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 27: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 28: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 29: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 30: South Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 31: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 32: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 33: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 34: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 35: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 36: East Asia Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 37: Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 38: Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 39: Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 40 Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 41: Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 42: Oceania Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 43: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Source
Table 44: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Therapeutic Drug
Table 45: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 46: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration
Table 47: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 48: MEA Psychedelic Drugs Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Psychedelic Drugs Market Historical Market Value (US$ Mn) Analysis, 2016-2020
Figure 2: Global Psychedelic Drugs Current and Future Market Value (US$ Mn), 2021-2031 & Y-o-Y Growth Trend Analysis
Figure 3: Psychedelic Drugs Market Absolute $ Opportunity, 2021–2031
Figure 4: Global Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 5: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Source, 2021-2031
Figure 6: Global Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 4: Global Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 5: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Therapeutic Drug, 2021-2031
Figure 6: Global Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 7: Global Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 8: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Indication, 2021-2031
Figure 9: Global Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 4: Global Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 5: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Route of Administration, 2021-2031
Figure 6: Global Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 10: Global Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 11: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Distribution Channel, 2021-2031
Figure 12: Global Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 13: Global Psychedelic Drugs Market Share Analysis (%) By Region, 2021 & 2031
Figure 14: Global Psychedelic Drugs Market Y-o-Y Growth (%) By Region, 2021-2031
Figure 15: Global Psychedelic Drugs Market Attractiveness Analysis, By Region
Figure 16 : North America Psychedelic Drugs Market Share, By Source (2021)
Figure 16 : North America Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 17: North America Psychedelic Drugs Market Share, By Indication (2021)
Figure 16 : North America Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 18 : North America Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 19 : North America Psychedelic Drugs Market Share, By Country (2021)
Figure 20 : North America Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 21: North America Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 22 : North America Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 23 : North America Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 23 : North America Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 24 : North America Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 23 : North America Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 25 : North America Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 26 : Latin America Psychedelic Drugs Market Share, By Source (2021)
Figure 27 : Latin America Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 28: Latin America Psychedelic Drugs Market Share, By Indication (2021)
Figure 29 : Latin America Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 30 : Latin America Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 31 : Latin America Psychedelic Drugs Market Share, By Country (2021)
Figure 32 : Latin America Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 33: Latin America Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 34 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 35 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 36 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 37 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 38 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 39 : Latin America Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 40 : Europe Psychedelic Drugs Market Share, By Source (2021)
Figure 41 : Europe Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 42: Europe Psychedelic Drugs Market Share, By Indication (2021)
Figure 43 : Europe Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 44 : Europe Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 45 : Europe Psychedelic Drugs Market Share, By Country (2021)
Figure 46 : Europe Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 47: Europe Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 48 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 49 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 50 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 51 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 52 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 53 : Europe Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 54 : South Asia Psychedelic Drugs Market Share, By Source (2021)
Figure 55 : South Asia Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 56: South Asia Psychedelic Drugs Market Share, By Indication (2021)
Figure 57 : South Asia Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 58 : South Asia Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 59 : South Asia Psychedelic Drugs Market Share, By Country (2021)
Figure 60 : South Asia Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 61: South Asia Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 62 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 63 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 64 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 65 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 66 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 67 : South Asia Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 68 : East Asia Psychedelic Drugs Market Share, By Source (2021)
Figure 69 : East Asia Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 70: East Asia Psychedelic Drugs Market Share, By Indication (2021)
Figure 71 : East Asia Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 72 : East Asia Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 73 : East Asia Psychedelic Drugs Market Share, By Country (2021)
Figure 74 : East Asia Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 75: East Asia Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 76 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 77 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 78 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 79 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 80 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 81 : East Asia Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 82 : Oceania Psychedelic Drugs Market Share, By Source (2021)
Figure 83 : Oceania Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 84: Oceania Psychedelic Drugs Market Share, By Indication (2021)
Figure 85 : Oceania Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 86 : Oceania Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 87 : Oceania Psychedelic Drugs Market Share, By Country (2021)
Figure 88 : Oceania Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 89: Oceania Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 90 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 91 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 92 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 93 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 94 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 95 : Oceania Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 96 : MEA Psychedelic Drugs Market Share, By Source (2021)
Figure 97 : MEA Psychedelic Drugs Market Share, By Therapeutic Drug (2021)
Figure 98: MEA Psychedelic Drugs Market Share, By Indication (2021)
Figure 99 : MEA Psychedelic Drugs Market Share, By Route of Administration (2021)
Figure 100 : MEA Psychedelic Drugs Market Share, By Distribution Channel (2021)
Figure 101 : MEA Psychedelic Drugs Market Share, By Country (2021)
Figure 102 : MEA Psychedelic Drugs Market Value (US$ Mn) Analysis, 2016–2020
Figure 103: MEA Psychedelic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 104 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Country
Figure 105 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Source
Figure 106 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Therapeutic Drug
Figure 107 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Indication
Figure 108 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Route of Administration
Figure 109 : MEA Psychedelic Drugs Market Attractiveness Analysis, By Distribution Channel
Figure 110 : U.S. Market Value Proportion Analysis
Figure 111 : Global Vs. U.S Growth Comparison
Figure 112: U.S. Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 113: U.S. Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 114: U.S. Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 115: U.S. Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 116: U.S. Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 117 : Canada Market Value Proportion Analysis
Figure 118 : Global Vs. Canada Growth Comparison
Figure 119: Canada Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 120: Canada Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 121: Canada Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 122: Canada Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 123: Canada Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 124 : Brazil Market Value Proportion Analysis
Figure 125 : Global Vs. Brazil Growth Comparison
Figure 126: Brazil Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 127: Brazil Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 128: Brazil Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 129: Brazil Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 130: Brazil Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 131 : Mexico Market Value Proportion Analysis
Figure 132 : Global Vs. Mexico Growth Comparison
Figure 133: Mexico Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 134: Mexico Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 135: Mexico Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 136: Mexico Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 137: Mexico Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 138 : Argentina Market Value Proportion Analysis
Figure 139 : Global Vs. Argentina Growth Comparison
Figure 140: Argentina Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 141: Argentina Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 142: Argentina Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 143: Argentina Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 144: Argentina Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 145 : Germany Market Value Proportion Analysis
Figure 146 : Global Vs. Germany Growth Comparison
Figure 147: Germany Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 148: Germany Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 149: Germany Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 150: Germany Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 151: Germany Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 152 : U.K. Market Value Proportion Analysis
Figure 153 : Global Vs. U.K. Growth Comparison
Figure 154: U.K. Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 155: U.K. Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 156: U.K. Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 157: U.K. Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 158: U.K. Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 159 : Italy Market Value Proportion Analysis
Figure 160 : Global Vs. Italy Growth Comparison
Figure 161: Italy Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 162: Italy Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 163: Italy Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 164: Italy Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 165: Italy Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 166 : Spain Market Value Proportion Analysis
Figure 167 : Global Vs. SPAIN Growth Comparison
Figure 168: Spain Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 169: Spain Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 170: Spain Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 171: Spain Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 172: Spain Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 173 : Russia Market Value Proportion Analysis
Figure 174 : Global Vs. RUSSIA Growth Comparison
Figure 175: Russia Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 176: Russia Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 177: Russia Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 178: Russia Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 179: Russia Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 180 : BENELUX Market Value Proportion Analysis
Figure 181 : Global Vs. BENELUX Growth Comparison
Figure 182: BENELUX Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 183: BENELUX Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 184: BENELUX Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 185: BENELUX Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 186: BENELUX Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 187 : China Market Value Proportion Analysis
Figure 188 : Global Vs. China Growth Comparison
Figure 189: China Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 190: China Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 191: China Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 192: China Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 193: China Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 194 : Japan Market Value Proportion Analysis
Figure 195 : Global Vs. Japan Growth Comparison
Figure 196: Japan Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 197: Japan Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 198: Japan Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 199: Japan Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 200: Japan Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 201 : South Korea Market Value Proportion Analysis
Figure 202 : Global Vs. South Korea Growth Comparison
Figure 203: South Korea Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 204: South Korea Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 205: South Korea Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 206: South Korea Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 207: South Korea Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 208 : India Market Value Proportion Analysis
Figure 209 : Global Vs. India Growth Comparison
Figure 210: India Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 211: India Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 212: India Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 213: India Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 214: India Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 215 : Thailand Market Value Proportion Analysis
Figure 216 : Global Vs. Thailand Growth Comparison
Figure 217: Thailand Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 218: Thailand Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 219: Thailand Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 220: Thailand Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 221: Thailand Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 222 : Indonesia Market Value Proportion Analysis
Figure 223 : Global Vs. Indonesia Growth Comparison
Figure 224: Indonesia Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 225: Indonesia Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 226: Indonesia Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 227: Indonesia Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 228: Indonesia Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 229 : Malaysia Market Value Proportion Analysis
Figure 230 : Global Vs. Malaysia Growth Comparison
Figure 231: Malaysia Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 232: Malaysia Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 233: Malaysia Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 234: Malaysia Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 235: Malaysia Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 236 : Australia Market Value Proportion Analysis
Figure 237 : Global Vs. Australia Growth Comparison
Figure 238: Australia Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 239: Australia Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 240: Australia Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 241: Australia Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 242: Australia Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 243 : New Zealand Market Value Proportion Analysis
Figure 244 : Global Vs. New Zealand Growth Comparison
Figure 245: New Zealand Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 246: New Zealand Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 247: New Zealand Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 248: New Zealand Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 249: New Zealand Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 250 : Turkey Market Value Proportion Analysis
Figure 251 : Global Vs. Turkey Growth Comparison
Figure 252: Turkey Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 253: Turkey Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 254: Turkey Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 255: Turkey Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 256: Turkey Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 257 : South Africa Market Value Proportion Analysis
Figure 258 : Global Vs. South Africa Growth Comparison
Figure 259: South Africa Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 260: South Africa Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 261: South Africa Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 262: South Africa Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 263: South Africa Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 264 : GCC Countries Market Value Proportion Analysis
Figure 265 : Global Vs. GCC Countries Growth Comparison
Figure 266: GCC Countries Psychedelic Drugs Market Share Analysis (%) By Source, 2021 & 2031
Figure 267: GCC Countries Psychedelic Drugs Market Share Analysis (%) By Therapeutic Drug, 2021 & 2031
Figure 268: GCC Countries Psychedelic Drugs Market Share Analysis (%) By Indication, 2021 & 2031
Figure 269: GCC Countries Psychedelic Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2031
Figure 270: GCC Countries Psychedelic Drugs Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Psychedelic Drugs Market
*Mail attachment includes 270 figures & 43 tables